Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6250892 | 0.84 | KMT2A (0.58) | KDM4EKMT2AMEN1XDHALDH1A1 | |
| SCHEMBL25703580 | 0.77 | MAPT (0.33) | KDM4EKMT2AMEN1ALDH1A1POLB | |
| SCHEMBL175251 | 0.74 | — | — | |
| SCHEMBL17045700 | 0.71 | TSHR (0.39) | KMT2AMEN1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL7883542 | 0.69 | KDM4E (0.47) | KDM4EKMT2AMEN1PKMABL1 | |
| SCHEMBL25138723 | 0.69 | HPGD (0.33) | ALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL16796009 | 0.69 | — | — | |
| SCHEMBL2193196 | 0.69 | PKM (0.55) | KDM4EKMT2AMEN1PKMABL1 | |
| SCHEMBL55228 | 0.69 | KDM4E (0.44) | KDM4EKMT2AMEN1PKMABL1 | |
| SCHEMBL811720 | 0.68 | MAPT (0.68) | KDM4EKMT2AMEN1PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242565-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF IN THE PREVENTION OR THERAPY OF DISEASES | Samsara Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4653432-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF IN THE PREVENTION OR THERAPY OF DISEASES | Samsara Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-113767106-B | Oxazaquinazolin-7 (8H) -ones, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-3430017-B1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | UNIV CALIFORNIA (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3430017-B1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | UNIV CALIFORNIA (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4116303-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | Loxo Oncology, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3350184-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | LOXO ONCOLOGY INC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220251109-A1 | OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-08-11 | — | — | US | disclosed |
| CN-114685516-A | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | 洛克索肿瘤学股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20030144266-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-07-31 | — | — | US | disclosed |
| US-6448253-B1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6407236-B1 | TUMOR DIAGNOSIS; ANTIINFLAMMATORY AGENTS; ANTIISCHEMIC AGENTS; ANTIDEPRESSANTS | MEDCO RESEARCH, INC. | 2002-06-18 | — | — | US | disclosed |
| WO-2000015231-A1 | ADENOSINE A3 RECEPTOR MODULATORS | MEDCO RESEARCH INC. (US) | 2000-03-23 | — | — | WO | disclosed |
| US-5958929-A | CONGESTIVE HEART FAILURE; HYPOTENSIVE AGENTS | SANOFI (FR) | 1999-09-28 | — | — | US | disclosed |
| US-5736548-A | CYCLIC GUANOSINE 3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; TREATING HEART FAILURE, HYPERTENSION | SANOFI (FR) | 1998-04-07 | — | — | US | disclosed |
| WO-1996028448-A1 | 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| US-5541187-A | HYPOTENSIVE AGENTS | STERLING WINTHROP INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1995001356-A1 | 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES HAVING ANTAGONISTIC ACTIVITY ON ADENOSINE A2 RECEPTOR | SCHERING-PLOUGH S.P.A. (IT) | 1995-01-12 | — | — | WO | disclosed |
| US-5294612-A | Hypotensive agents and cardiovascular disorders | STERLING WINTHROP INC. (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251109-A1 | OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | KRAS, NRAS, WEE1 | KDM4E 2618/4885KMT2A 1766/4885MEN1 976/4885 |
| US-20030144266-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | KDM4E 4491/4885KMT2A 2948/4885MEN1 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.